28bio is committed to promoting transparency, integrity, and objectivity in research and business practices. In compliance with applicable regulations, this Financial Conflict of Interest (FCOI) Policy ensures that financial interests do not improperly influence research or decision-making.
All employees, researchers, and collaborators must disclose any significant financial interests (SFI) that could directly or indirectly affect 28bio’s business, research, or regulatory decisions.
Disclosed financial interests will be reviewed by an appointed committee to determine if a conflict exists. If a conflict is identified, a management plan will be implemented to mitigate any potential influence on research integrity or business operations.
Individuals engaged in research must complete FCOI training prior to participation and renew their training every four years or when policy updates occur.
28bio will report identified FCOIs to applicable regulatory bodies as required by law, including funding agencies such as the NIH, ensuring compliance with federal guidelines.
Failure to disclose financial interests or comply with management plans may result in corrective actions, including termination of employment, loss of research privileges, or legal consequences.
For any questions or to disclose a potential financial conflict of interest, contact 28bio Investor Relations at investor@28bio.com
